Beam Therapeutics

Contributing Author

Recent Articles by Beam Therapeutics

Jun-13	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
Jun-03	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease BEAM GlobeNewswire
May-29	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-14	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
May-13	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference BEAM GlobeNewswire
May-12	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-06	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights BEAM GlobeNewswire